Two Sigma Investments
XENE icon

Two Sigma Investments’s Xenon Pharmaceuticals XENE Stock Holding History

Two Sigma Investments’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.2M Buy
1,642,848
+1,036,763
+171% +$57.6M 0.07% 309
2026
Q1 		$35.2M Buy
606,085
+169,342
+39% +$7.8M 0.03% 652
2025
Q4 		$19.6M Buy
+436,743
New +$18.3M 0.03% 735
2025
Q2 		– Sell
-236,983
Closed -$7.95M – 3585
2025
Q1 		$7.95M Sell
236,983
-36,369
-13% -$1.38M 0.02% 864
2024
Q4 		$10.7M Buy
273,352
+29,773
+12% +$1.23M 0.02% 725
2024
Q3 		$9.59M Buy
243,579
+48,450
+25% +$1.95M 0.02% 777
2024
Q2 		$7.61M Sell
195,129
-79,497
-29% -$3.18M 0.02% 819
2024
Q1 		$11.8M Sell
274,626
-65,389
-19% -$3.01M 0.03% 600
2023
Q4 		$15.7M Buy
340,015
+259,382
+322% +$9.16M 0.04% 497
2023
Q3 		$2.75M Buy
80,633
+62,000
+333% +$2.32M 0.01% 1207
2023
Q2 		$717K Buy
18,633
+7,179
+63% +$285K ﹤0.01% 2147
2023
Q1 		$410K Buy
+11,454
New +$423K ﹤0.01% 2291
2022
Q4 		– Sell
-55,974
Closed -$2.02M – 3112
2022
Q3 		$2.02M Buy
+55,974
New +$2.01M 0.01% 1144
2022
Q2 		– Sell
-232,650
Closed -$7.11M – 2984
2022
Q1 		$7.11M Sell
232,650
-45,693
-16% -$1.37M 0.02% 758
2021
Q4 		$8.7M Buy
278,343
+108,667
+64% +$3.25M 0.02% 875
2021
Q3 		$2.59M Buy
169,676
+84,458
+99% +$1.47M 0.01% 1736
2021
Q2 		$1.59M Buy
85,218
+8,512
+11% +$157K ﹤0.01% 2082
2021
Q1 		$1.37M Buy
76,706
+26,145
+52% +$443K ﹤0.01% 2028
2020
Q4 		$778K Buy
50,561
+576
+1% +$6.74K ﹤0.01% 2193
2020
Q3 		$553K Sell
49,985
-70,130
-58% -$825K ﹤0.01% 2166
2020
Q2 		$1.51M Buy
120,115
+31,510
+36% +$401K 0.01% 1255
2020
Q1 		$1M Buy
88,605
+11,788
+15% +$168K 0.01% 1410
2019
Q4 		$1.01M Buy
+76,817
New +$808K ﹤0.01% 2179
2019
Q2 		– Sell
-58,149
Closed -$591K – 3715
2019
Q1 		$591K Sell
58,149
-142,112
-71% -$1.2M ﹤0.01% 2167
2018
Q4 		$1.26M Buy
200,261
+123,676
+161% +$1.1M ﹤0.01% 1494
2018
Q3 		$1.01M Buy
+76,585
New +$887K ﹤0.01% 1976

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments's XENE Position: Q2 2026 in Review

Two Sigma Investments increased its Xenon Pharmaceuticals (XENE) stake by 171% in Q2 2026, buying an estimated $57.6M and bringing the position to 1,642,848 shares worth $99.2M. The position accounts for 0.07% of the portfolio, ranked #309.

Two Sigma Investments first reported a position in XENE in Q3 2018 and has held it in 26 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Two Sigma Investments held 1,642,848 shares of Xenon Pharmaceuticals worth $99.2M as of Q2 2026.
  • Two Sigma Investments bought 1,036,763 Xenon Pharmaceuticals shares in Q2 2026, an estimated $57.6M.
  • Xenon Pharmaceuticals made up 0.07% of Two Sigma Investments's portfolio in Q2 2026, its #309 holding.
  • Two Sigma Investments first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.